New recurrent UTI guideline: What urologists need to know
Oct 7, 2019 · New recurrent UTI guideline: What urologists need to know. The AUA/CUA/SUFU guide focuses on a combination of symptoms and positive cultures. Uncomplicated urinary tract infection is one of the most common indications for antimicrobial exposure in otherwise healthy women. In the past 20 years, antimicrobial resistance among uropathogens has ...
Shock wave therapy: ED cure or unproven treatment? - Urology …
Aug 6, 2019 · Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important unanswered questions, including which patients are ideal candidates and which protocol and devices are best. Without answers, offering the ED treatment ...
Long-term results of Rezum therapy for patients with large prostates
Dec 23, 2021 · So, the retreatment rate for our small prostate cohort was 4.4%, which is in line with the results demonstrated from the original WATER clinical trial, 3 which also had a retreatment rate of 4.4%. For our large prostate cohort, this subset of patients had a retreatment rate of 18.4%, so a little less than one in five patients required ...
Transgender surgery: Videos demonstrate cutting-edge techniques
Apr 6, 2017 · Transgender surgery: Videos demonstrate cutting-edge techniques. In these videos, expert surgeons demonstrate robot-assisted penile inversion vaginoplasty, single-stage metoidioplasty, and simple orchiectomy for transgender patients. Transgender surgery is a burgeoning field in urology and, with nearly 700,000 people in the United States alone ...
Advancements in Minimally Invasive Surgical Options for the …
Mar 31, 2022 · Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate affecting more than 40 million men in the United States with an associated prevalence that increases from 40% to 80% among men 50 to 70 years of age, respectively. 1,2 Progression of BPH leads to the subsequent development of lower urinary tract symptoms (LUTS), which most commonly include frequent urination ...
5-year Rezum study results show low rates of erectile and …
Sep 23, 2021 · What we can say about MIST, minimally invasive surgical treatment, and in the current guidelines the real players are Rezum and UroLift, there is reliable data to 5 years, but not beyond. And we know about retreatment rates within 5 years. Surgical retreatment rates in terms of Rezum at 5 years is 4.4%, relatively low.
EpiSwitch Prostate Screening blood test launches on US market
Sep 26, 2023 · The EpiSwitch Prostate Screening (PSE) blood test has been clinically validated and is now available to men in the US who are being screened for prostate cancer, announced Oxford BioDynamics, the developer of the test, in a news release. 1. "It feels wholly appropriate that the early launch of the test coincides with Prostate Cancer Awareness ...
Dr. Elterman discusses Rezum and Aquablation for patients with BPH
Sep 10, 2021 · Dean Elterman, MD. At the 2021 American Urological Association annual meeting, Dean Elterman, MD, MSc, FRCSC, presented the studies “Rezūm water vapor therapy for large volume (≥80 mL) benign prostatic enlargement: large, multi-center cohort,” 1 and “Pooled analysis of bladder function post-Aquablation.” 2.
Expert explains latest findings with oral softgel capsule for ...
Nov 11, 2021 · In 2019, the FDA reapproved a new oral formulation of testosterone undecanoate (Jatenzo), which is taken twice a day as capsules and absorbed through the intestine. The difference between this compound and other compounds that were orally administered is that this new formulation is absorbed through the lymphatic system, rather than going ...
177Lu-PSMA-617 meets rPFS end point in phase 3 trial for mCRPC
Oct 23, 2023 · Results from the phase 3 PSMAfore (NCT04689828) trial indicate that treatment with 177 -Lu-PSMA [prostate-specific membrane antigen]-617 (Pluvicto) met its primary end point of radiographic progression-free survival (rPFS) and showed a favorable safety profile in patients with metastatic castration-resistant prostate cancer (mCRPC) who were ...